Psoriasis Drugs Market (2026 - 2033) Size, Share & Trends Analysis Report By Class(Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids), By Treatment, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts

Psoriasis Drugs Market Summary

The global psoriasis drugs market size was valued at USD 23.3 billion in 2025 and is projected to grow from USD 25.7 billion in 2026 to USD 54.9 billion by 2033, at a CAGR of 11.4% from 2026 to 2033. North America psoriasis drugs market held the largest share of 38.3% of the global market in 2025. The psoriasis drugs market is witnessing strong growth driven by advances in immunomodulators, increasing adoption of biologic therapies, and favorable reimbursement support across developed healthcare markets.

Continuous research and development activities are contributing to treatment innovation, particularly for moderate to severe psoriasis cases, thereby supporting demand for targeted therapies. A major market trend is the increasing competition from biosimilars, which is reshaping the competitive landscape for established biologics and improving treatment accessibility. Growing acceptance of biosimilars among healthcare providers and payers is helping reduce herapy costs and expand patient access, especially in cost-sensitive markets. In addition, the market continues to shift toward advanced interleukin inhibitors and targeted oral therapies due to their improved efficacy, longer treatment durability, and favorable clinical outcomes compared to conventional systemic treatments.The market is also experiencing a strong shift toward precision-based psoriasis management, supported by the increasing preference for targeted biologics and next-generation oral therapies. Interleukin inhibitors targeting IL-17 and IL-23 pathways continue to gain significant commercial traction due to their high skin clearance rates, rapid onset of action, and sustained therapeutic response. Pharmaceutical companies are actively focusing on lifecycle management strategies, label expansions, and development of improved formulations to strengthen product positioning in the competitive immunology segment. In addition, increasing physician awareness regarding long-term disease management and comorbidity reduction is contributing to higher adoption of advanced psoriasis therapeutics.

Rising prevalence of chronic inflammatory skin disorders and increasing demand for long-term disease management therapies continue to support the growth of the psoriasis drugs market. The market is benefiting from higher adoption of advanced biologics and targeted therapies that offer improved efficacy, better symptom control, and enhanced patient outcomes compared to conventional treatments. In addition, increasing healthcare expenditure, expanding access to specialty dermatology care, and growing awareness regarding early diagnosis and treatment are further contributing to market expansion. Continuous product innovation, broader biosimilar availability, and ongoing regulatory support for novel psoriasis therapies are expected to sustain competitive development and create favorable growth opportunities for the market during the forecast period.

Market Dynamics

Market Concentration & Characteristics

The Psoriasis Drugs Market demonstrates a high degree of innovation driven by continuous advancements in targeted immunology therapies and precision-based treatment approaches. Pharmaceutical companies are actively developing next-generation biologics, oral small-molecule inhibitors, and improved drug delivery formulations to enhance treatment efficacy, safety, and patient convenience. Innovation within the market is particularly focused on interleukin-targeting therapies, including IL-17 and IL-23 inhibitors, which continue to transform moderate to severe psoriasis management. The market is also witnessing increasing development of biosimilars and novel oral therapies aimed at improving affordability and expanding patient access. In addition, ongoing research into long-term disease control, personalized treatment strategies, and combination therapies continues to strengthen innovation across the psoriasis therapeutics landscape.

The Psoriasis Drugs Market presents moderate to high barriers to entry due to the significant investment required for biologic drug development, clinical trials, and regulatory approvals. Developing advanced psoriasis therapies involves complex research processes, extensive safety and efficacy evaluations, and long product development timelines, particularly for biologics and targeted immunology treatments. Established pharmaceutical companies also maintain strong market positions through broad product portfolios, patent protection, and extensive commercialization networks. In addition, stringent regulatory requirements and reimbursement evaluation processes create additional challenges for new entrants seeking market penetration. The market further demands substantial manufacturing capabilities and specialized expertise for biologic production, limiting entry opportunities for smaller companies.

The psoriasis drugs market is strongly influenced by regulatory frameworks related to biologic approvals, biosimilar commercialization, clinical trial standards, and long-term drug safety monitoring. Regulatory authorities such as the U.S. Food and Drug Administration and the European Medicines Agency continue to support the approval of innovative psoriasis therapies and biosimilars, contributing to increased treatment availability and market competition. Favorable regulatory pathways for biosimilars are helping expand patient access to cost-effective therapies, particularly in developed healthcare markets. However, stringent regulatory requirements related to efficacy validation, immunogenicity assessment, manufacturing quality, and pharmacovigilance increase development timelines and operational costs for manufacturers. In addition, evolving regulations surrounding targeted immunology therapies and specialty biologics continue to influence product development, market entry strategies, and commercialization activities across the psoriasis therapeutics industry.

Topical therapies, conventional systemic drugs, phototherapy, and non-biologic immunosuppressants continue to serve as alternatives to advanced biologic and targeted psoriasis treatments, particularly in mild-to-moderate disease cases. Many patients in cost-sensitive markets still rely on traditional therapies due to their lower cost, easier accessibility, and established clinical usage. In addition, supportive skincare products and light-based treatment approaches may assist to manage symptoms in selected patient populations, reducing dependence on high-cost biologic therapies. However, increasing preference for targeted biologics and interleukin inhibitors is continuing to shift treatment adoption toward therapies offering superior efficacy, sustained disease control, and improved long-term patient outcomes.

Geographical expansion within the psoriasis therapeutics industry is being driven by increasing healthcare access, rising dermatology awareness, and growing availability of advanced biologic therapies across emerging markets. Pharmaceutical companies are actively strengthening their presence in Asia-Pacific, Latin America, and Middle Eastern countries through regulatory approvals, commercialization partnerships, and broader distribution strategies. Expanding biosimilar availability is further supporting market penetration in cost-sensitive regions by improving affordability and treatment accessibility. In addition, improving healthcare infrastructure and rising investments in specialty dermatology care are contributing to higher diagnosis and treatment rates in developing economies. Ongoing expansion activities by global pharmaceutical manufacturers are expected to create significant growth opportunities across underserved regional markets during the forecast period.

Class Insights

The tumor necrosis factor inhibitors segment dominated the market with the largest revenue share of 40.8% in 2025, widely used for the management of moderate-to-severe disease. These therapies function by blocking TNF-α, a key inflammatory cytokine involved in psoriasis pathogenesis, thereby reducing skin inflammation and disease progression. Despite the emergence of newer biologic classes, TNF inhibitors remain highly relevant due to extensive physician experience and established long-term efficacy data. The segment also benefits from biosimilar penetration, which has improved affordability and expanded access in cost-sensitive markets. However, its relative market share is gradually moderating in developed regions due to increasing preference for next-generation targeted therapies. Overall, the segment remains a critical, cost-effective treatment backbone within the broader biologics landscape of psoriasis care. For instance, in August 2025, a cohort-based study published  in Rheumatology reported that patients with psoriasis receiving TNF inhibitor therapy showed a lower incidence of progression to psoriatic arthritis compared to non-biologic treatment cohorts, reinforcing the long-term disease-modifying relevance of this drug class in inflammatory dermatology.

The interleukin inhibitors segment is projected to grow at a CAGR of 12.8% over the forecast period, driven by rapid advancements in targeted immunology and a deeper understanding of cytokine-mediated inflammatory pathways. The interleukin inhibitors segment has emerged as a leading growth class within the psoriasis drugs market. These therapies selectively target key interleukin pathways involved in disease pathogenesis, resulting in improved skin clearance rates, sustained remission, and enhanced clinical outcomes for moderate-to-severe psoriasis patients.

Furthermore, the segment has significantly reshaped treatment paradigms by offering higher efficacy and better safety profiles compared to conventional systemic therapies and earlier biologic classes. Increasing physician preference for precision-based treatment approaches, along with improved dosing convenience and long-term disease control, continues to support strong clinical adoption. Ongoing innovation in pathway-specific biologics and next-generation molecules is further intensifying competition and expanding therapeutic options across global markets. Overall, interleukin inhibitors are becoming the dominant driver of biologic growth in psoriasis care, steadily redefining treatment standards worldwide. For instance, in March 2026, the U.S. FDA approved Johnson & Johnson’s ICOTYDE (icotrokinra), a first-in-class oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a major advancement toward convenient, targeted immunology-based therapies with strong clinical efficacy and favorable safety outcomes.

Treatment Insights

The biologics segment held the largest revenue share of 46.4% in 2025, driven by strong clinical adoption of targeted immunology therapies for moderate-to-severe disease management. These therapies, including TNF-α, IL-12/23, IL-17, and IL-23 inhibitors, are increasingly preferred for their high efficacy and ability to deliver sustained disease control. Growing shift toward precision-based treatment approaches is accelerating the transition from conventional systemic therapies to biologics. IL-17 and IL-23 inhibitors are witnessing robust demand owing to superior skin clearance outcomes and improved safety profiles. Extended dosing intervals of newer biologics are further enhancing patient compliance and treatment continuity. Continuous pipeline advancements and the introduction of next-generation monoclonal antibodies are expanding the overall treatment landscape within this segment. Increasing physician preference for targeted therapies in refractory and difficult-to-treat cases is further supporting market penetration. Overall, continuous innovation and expanding utilization across clinical settings are reinforcing the biologics segment as a key growth driver in the psoriasis drugs market.

The topicals segment is projected to grow at a CAGR of 12.0% from 2026 to 2033, driven by its widespread use as a first-line treatment for mild-to-moderate psoriasis. These therapies, including corticosteroids, vitamin D analogs, retinoids, and calcineurin inhibitors, are extensively prescribed due to their localized action and ability to directly reduce inflammation and scaling at the affected skin sites. Growing preference for non-invasive and cost-effective treatment options is supporting sustained demand for topical formulations across both developed and emerging markets. Improved formulation technologies, such as enhanced drug penetration systems and combination therapies, are further strengthening clinical outcomes and patient adherence. The segment continues to benefit from its role in combination regimens alongside systemic and biologic therapies for better disease management. Increasing availability of advanced topical agents with improved safety profiles is also expanding their utilization in long-term care. Overall, the topical segment remains a foundational and highly relevant treatment category in the psoriasis drugs market.

Route of Administration Insights

The parenteral segment dominated the market with the largest revenue share of 41.9% in 2025 and is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of injectable biologic therapies for moderate-to-severe disease management. These therapies are widely preferred for their high clinical efficacy and ability to provide sustained long-term disease control. The growing shift toward targeted immunology-based treatments has significantly strengthened the role of injectable administration in routine clinical practice. Subcutaneous formulations are witnessing strong uptake owing to improved patient convenience compared to intravenous options. Advancements in self-administration devices and prefilled syringes are further enhancing treatment adherence and ease of use. Ongoing introduction of next-generation biologics is expanding the injectable treatment landscape and supporting broader clinical adoption. Overall, the parenteral segment remains a key growth contributor in the psoriasis drugs market, driven by innovation and rising biologic utilization. For instance, in December 2025, Innovent Biologics reported successful Phase 3 results for its IL-23p19 monoclonal antibody picankibart injection, which achieved key efficacy endpoints in moderate-to-severe plaque psoriasis, reinforcing continued innovation in injectable biologics and strengthening the long-acting biologics landscape in the market.

The topical segment is projected to grow at a significant CAGR from 2026 to 2033, driven by its extensive use as first-line therapy for mild-to-moderate disease management. These formulations are widely preferred due to their localized action, favorable safety profile, and ability to directly target cutaneous inflammation without systemic exposure. The segment continues to benefit from strong demand for cost-effective and non-invasive treatment options across both developed and emerging healthcare markets. Increasing use of topical agents in combination regimens with systemic and biologic therapies is further enhancing their clinical relevance in comprehensive disease management strategies.

In addition, advancements in formulation science, including improved skin penetration technologies and optimized drug delivery systems, are strengthening therapeutic performance and patient adherence. For instance, in June 2025, research activity in nanostructured and advanced topical gels demonstrated improved drug penetration and anti-inflammatory outcomes, indicating ongoing R&D focus on enhancing topical efficacy through novel delivery technologies and formulation science. Overall, continuous innovation and sustained clinical utilization are reinforcing the topical segment as a stable and essential contributor to the psoriasis drugs market.

Distribution Channel Insights

The hospital pharmacies segment dominated the market with the largest revenue share of 42.1% in 2025 and is expected to grow at the fastest CAGR during the forecast period. The segment growth can be attributed to the administration and dispensing of advanced therapies for moderate-to-severe disease cases. These settings play a critical role in the distribution of biologics and other prescription-only medications that require physician supervision and specialized handling. The segment benefits from the increasing use of injectable therapies, which are often initiated and monitored within hospital environments to ensure treatment efficacy and patient safety. Strong integration between dermatology departments and hospital pharmacy services further supports timely access to advanced psoriasis treatments. Hospital pharmacies also serve as key centers for initiating first-line biologic therapy before transitioning patients to maintenance care settings. Growing hospitalization rates for complex dermatological cases and increasing adoption of specialty drugs are reinforcing demand through this channel. Overall, the hospital pharmacies segment remains a vital distribution channel in the psoriasis drugs market, supported by rising biologic utilization and specialized treatment requirements.

The retail pharmacies segment is projected to grow at a significant CAGR over the forecast period, driven by its wide accessibility and strong presence across both urban and semi-urban healthcare settings. These channels play a crucial role in ensuring the availability of topical, oral, and supportive psoriasis therapies, particularly for mild-to-moderate cases requiring routine dispensing. The segment continues to benefit from rising patient preference for convenient, quick access to prescription medications, without prolonged hospital visits. Strong integration of retail pharmacies with prescription networks and dermatology clinics is further supporting consistent drug flow and patient adherence to therapy. Growing penetration of organized pharmacy chains and digital pharmacy platforms is enhancing product availability and service efficiency. The rising demand for chronic disease management and repeat prescriptions is also reinforcing the importance of retail distribution channels. Overall, the retail pharmacies segment remains a key and stable contributor to the psoriasis drugs market, supported by accessibility, convenience, and strong prescription fulfillment rates.

Regional Insights

North America held the largest psoriasis drugs market share of 38.3% in 2025, driven by high adoption of biologic therapies, strong healthcare infrastructure, and increasing diagnosis rates of chronic inflammatory skin disorders across the region. The U.S. accounts for a significant share of the regional market due to the presence of major pharmaceutical manufacturers, broad availability of advanced psoriasis treatments, and favorable insurance coverage for specialty therapies. Demand for interleukin inhibitors and targeted oral therapies is increasing as healthcare providers increasingly prefer treatments offering improved efficacy, sustained disease control, and convenient administration. The market is also witnessing rising biosimilar competition, particularly for established biologics, which is contributing to improved treatment accessibility and pricing pressure within the competitive landscape. In addition, continuous regulatory approvals, product launches, and commercialization of next-generation immunology therapies are supporting market expansion across North America. Growing patient awareness regarding long-term disease management and access to specialized dermatology care further continue to strengthen treatment adoption throughout the region.

U.S. Psoriasis Drugs Market Trends

Psoriasis drugs market in the U.S. is driven by high utilization of biologic therapies, increasing diagnosis rates of moderate-to-severe psoriasis, and strong access to specialized dermatology care. The country represents a major regional market due to the presence of leading pharmaceutical manufacturers, advanced healthcare infrastructure, and broad availability of innovative psoriasis treatments. Growing adoption of interleukin inhibitors and targeted oral therapies is further supporting market growth as healthcare providers increasingly prefer therapies offering improved efficacy and sustained disease control. In addition, rising biosimilar competition for established biologics is contributing to improved treatment accessibility and increasing competitive pricing pressure within the market. Favorable reimbursement frameworks, ongoing regulatory approvals, and expanding commercialization of advanced immunology therapies continue to strengthen the treatment landscape across the United States. Moreover, increasing patient awareness regarding long-term psoriasis management and ongoing investments in immunology-focused research are expected to support continued market expansion during the forecast period.

Europe Psoriasis Drugs Market Trends

Psoriasis drugs market in Europe shows steady growth driven by increasing adoption of biologic therapies, expanding biosimilar penetration, and strong public healthcare support across major European countries. Germany, the United Kingdom, and France continue to represent key regional markets due to advanced dermatology care infrastructure, favorable reimbursement frameworks, and high utilization of interleukin inhibitors for moderate-to-severe psoriasis management. The region is witnessing a growing preference for cost-effective biosimilars as healthcare systems increasingly focus on reducing biologic treatment expenditure while maintaining broad patient access to advanced therapies. In addition, strong regulatory support from the European Medicines Agency and established health technology assessment systems are supporting the commercialization of innovative psoriasis treatments across Europe. Pharmaceutical companies are also expanding real-world evidence generation and value-based access strategies to strengthen product adoption within highly regulated European healthcare systems. Furthermore, increasing awareness of long-term disease management and rising demand for targeted immunology therapies continue to support sustained market expansion across the region.

The UK psoriasis drugs market is experiencing strong growth, supported by a high prevalence of chronic plaque psoriasis, a well-established NHS-driven healthcare system, and increasing adoption of advanced biologics such as IL-17 and IL-23 inhibitors. The market is witnessing a clear shift from conventional systemic therapies and topical treatments toward targeted biologics due to their superior efficacy and long-term disease control. Rising availability of biosimilars is improving treatment accessibility and putting pressure on branded biologics, particularly in cost-sensitive NHS prescribing pathways. Regulatory support from agencies such as the MHRA, along with structured reimbursement and health technology assessment processes, continues to shape treatment adoption and market entry strategies. In addition, increasing dermatology awareness and early diagnosis are expanding the treated patient pool across the UK. Overall, the market is characterized by strong innovation-led growth and a steady transition toward high-value biologic and targeted therapies.

Psoriasis drugs market in Germany is shaped by a highly structured insurance-driven healthcare framework, where treatment decisions are strongly influenced by evidence-based clinical guidelines and cost-effectiveness considerations. Physicians in dermatology clinics and hospital settings demonstrate a high preference for advanced biologic therapies, particularly newer interleukin-targeted agents, for managing moderate-to-severe cases. The market also reflects strong integration of health technology assessment outcomes, which play a key role in determining reimbursement eligibility and prescribing patterns. Biosimilars are gaining notable acceptance, supported by physician familiarity and ongoing pressure to optimize statutory health insurance expenditure. Increasing focus on early intervention and long-term disease management is further supporting sustained demand for advanced systemic treatments. Overall, the German market is characterized by disciplined treatment pathways, strong reimbursement governance, and a gradual but steady shift toward high-value biologic and biosimilar therapies.

The France psoriasis drugs market is shaped by a tightly coordinated public healthcare system where treatment pathways are strongly influenced by national reimbursement rules and hospital prescribing committees. Access to advanced therapies is largely mediated through public coverage mechanisms, which prioritize clinical value and long-term cost efficiency in treatment selection. The market is witnessing a steady shift toward biologic and other targeted immunology treatments, supported by increasing dermatologist preference for therapies offering sustained disease control in moderate-to-severe cases. Conventional systemic drugs and topical agents continue to be used, particularly in early-stage management, but their role is gradually being complemented by advanced options. Biosimilar uptake is expanding as healthcare authorities emphasize budget optimization and wider patient access to high-cost therapies. Overall, the market reflects a centrally regulated, value-driven treatment environment with growing integration of advanced biologics and biosimilars in routine dermatology practice.

Asia-Pacific Psoriasis Drugs Market Trends

Psoriasis drugs market in Asia Pacific is expected to register the fastest CAGR of 13.1% over the forecast period driven by a large undiagnosed patient pool, improving dermatology infrastructure, and increasing awareness of chronic autoimmune skin conditions across emerging economies. Rising healthcare expenditure and expanding insurance coverage in countries such as China, India, and South Korea are supporting broader access to advanced treatment options. The market demonstrates a growing transition from conventional therapies toward advanced systemic and biologic treatments, although affordability constraints continue to influence adoption patterns. Urban centers are leading in the uptake of newer therapies, while rural regions still rely heavily on traditional treatment approaches due to cost and accessibility limitations. The presence of domestic manufacturers and increasing availability of lower-cost biologics are further reshaping competitive dynamics across the region. Overall, the market is characterized by heterogeneous adoption patterns, strong growth potential, and gradual penetration of advanced immunology-based therapies.

The Japan psoriasis drugs market is characterized by a highly structured healthcare system with strong emphasis on clinical evidence, safety standards, and long-term treatment outcomes. The market demonstrates steady adoption of advanced systemic and biologic therapies, supported by favorable reimbursement coverage under the national health insurance framework. Dermatology specialists play a central role in treatment selection, with a preference for well-validated therapies for moderate-to-severe psoriasis cases. Conventional treatments continue to be used in early-stage management, although their share is gradually declining with increasing use of targeted therapies. The presence of an aging population and rising awareness of chronic autoimmune skin conditions further support sustained demand for long-term disease control options. Overall, the market reflects a mature, quality-driven landscape with gradual alignment toward broader Asia Pacific trends of expanding access to advanced immunology-based treatments.

Psoriasis drugs market in China is expanding steadily, driven by a large patient base, rising diagnosis rates, and strengthening dermatology capabilities within tiered hospital systems. Treatment patterns are heavily shaped by hospital-based prescribing and inclusion within the National Reimbursement Drug List, which significantly influences patient access and affordability. While topical and conventional systemic therapies continue to dominate overall treatment volumes, advanced targeted therapies are increasingly used in higher-tier urban hospitals for moderate-to-severe cases. Domestic pharmaceutical companies are playing a growing role by offering competitively priced biologics and biosimilars, which are improving treatment accessibility across cost-sensitive segments. Imported innovative therapies are present but often face pricing pressure and limited uptake outside major urban centers due to reimbursement constraints. Overall, the market reflects a policy-driven, cost-sensitive ecosystem with gradual but uneven adoption of advanced immunology-based treatments.

Latin America Psoriasis Drugs Market Trends

Psoriasis drugs market in Latin America is characterized by a highly fragmented healthcare landscape, with significant disparities in access to advanced dermatology treatments across and within countries such as Brazil, Mexico, and Argentina. Conventional systemic therapies and topical agents continue to account for a substantial share of treatment utilization, particularly within public healthcare systems constrained by budget limitations. Adoption of advanced targeted therapies remains concentrated in private healthcare facilities located in major urban centers, reflecting pronounced differences in affordability and reimbursement coverage. Out-of-pocket expenditure continues to play a key role in determining treatment choice, limiting broader penetration of high-cost innovative therapies. However, gradual improvements in regulatory frameworks and increasing presence of multinational pharmaceutical companies are enhancing access to newer treatment options. Overall, the market reflects a structurally uneven but slowly evolving landscape, with innovation uptake primarily restricted to urban private care settings.

Psoriasis drugs market in Brazil represents the most structured segment within Latin America, supported by the coexistence of a universal public healthcare system (SUS) and a rapidly expanding private healthcare sector. Treatment utilization is primarily concentrated in conventional systemic and topical therapies within the public system, driven by budgetary constraints and standardized formulary access. Advanced therapies are predominantly adopted in private dermatology practices across major urban centers, reflecting significant disparities in treatment accessibility. Reimbursement processes and administrative approvals within the public healthcare framework continue to play a decisive role in limiting the pace of adoption of newer therapies. The presence of multinational pharmaceutical companies, along with strengthening local distribution networks, is gradually improving the availability of innovative treatment options. Overall, the market reflects a dual-access structure with uneven but steadily evolving penetration of advanced psoriasis therapies, consistent with broader Latin American market dynamics.

Middle East & Africa Psoriasis Drugs Market Trends

Psoriasis drugs market in MEA is characterized by pronounced regional disparity, with advanced treatment access largely concentrated in Gulf Cooperation Council (GCC) countries, while several African markets remain at a comparatively early stage of dermatology care development. Treatment adoption is primarily driven by conventional systemic therapies and topical agents across public healthcare systems, reflecting infrastructure and affordability limitations. In contrast, private and specialty healthcare providers in countries such as Saudi Arabia and the United Arab Emirates demonstrate higher utilization of advanced therapies for moderate-to-severe cases, supported by stronger healthcare investment capacity. Limited disease awareness, underdiagnosis, and diagnostic delays continue to restrict overall treatment penetration across multiple African regions. Market expansion efforts by pharmaceutical companies are increasingly focused on strategic partnerships, import-based supply channels, and selective country-level entry strategies. Overall, the market is highly fragmented in nature with a clear GCC-led adoption pattern and gradual but uneven progression toward advanced psoriasis therapeutics. 

Psoriasis drugs market in Saudi Arabia is supported by strong government-led healthcare investment and ongoing expansion of specialized dermatology infrastructure under national transformation initiatives. Treatment adoption is increasingly concentrated in tertiary care and specialty hospitals, where advanced systemic and targeted therapies are prioritized for moderate-to-severe cases based on clinical protocols and formulary approvals. Public healthcare coverage continues to play a central role in ensuring patient access, while the private sector contributes to broader availability of innovative treatment options. Hospital procurement systems and reimbursement frameworks significantly influence prescribing patterns and therapy selection across care settings. The presence of multinational pharmaceutical companies, alongside growing localization of healthcare services, is reinforcing market maturity and access to advanced therapies. Overall, the market reflects a structured and investment-driven environment with progressive integration of advanced psoriasis treatment options within a regulated healthcare system.

Key Psoriasis Drugs Company Insights

AbbVie Inc. and Amgen Inc. continue to strengthen their positions in the psoriasis drugs market through expanding portfolios of advanced biologics targeting chronic immune-mediated pathways. Johnson & Johnson Services, Inc. and Novartis AG remain key players, focusing on next-generation targeted therapies and lifecycle management of established biologic products. Eli Lilly and Company is advancing innovative immunology-based pipelines, supported by robust clinical development programs in inflammatory dermatology indications. Celgene Corporation and UCB S.A. contribute significantly through specialized immunomodulatory therapies addressing moderate-to-severe psoriasis cases. Merck and Boehringer Ingelheim International GmbH are enhancing their presence through strategic investments in immunodermatology research and novel therapeutic approaches. The market is characterized by intense competition, continuous pipeline innovation, and a strong shift toward targeted biologic therapies driven by evolving treatment guidelines and increasing precision medicine adoption.

Key Psoriasis Drugs Companies

The following key companies have been profiled for this study on the psoriasis drugs market

• AbbVie Inc.

• Amgen Inc.

• Boehringer Ingelheim International GmbH

• Celgene Corporation

• Eli Lilly and Company

• Johnson & Johnson Services, Inc.

• Merck

• Novartis AG

• UCB S.A. 

Competitive Benchmarking

Recent Developments

• In February 2026, Eli Lilly strengthened its immunology pipeline through continued advancement of IL-23 and JAK pathway-targeting therapies, supported by strong clinical-stage investments in autoimmune and inflammatory disease biologics.

• In May 2025, Arcutis Biotherapeutics received U.S. FDA approval for ZORYVE (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in adults and adolescents, highlighting continued innovation in non-steroidal topical therapies and growing industry focus on advanced patient-friendly dermatology formulations.

• In March 2025, Johnson & Johnson shared new data from its Phase 3 trial for icotrokinra (JNJ-2113), an investigational oral IL-23 receptor blocker for moderate to severe plaque psoriasis. In the ICONIC-LEAD study, 65% of patients achieved clear or almost clear skin (IGA 0/1) and 50% achieved PASI 90 by Week 16, compared to 8% and 4% on placebo (p<0.001).

Psoriasis Drugs Market Report Scope

Global Psoriasis Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region:

• Class Outlook (Revenue, USD Billion, 2021 - 2033)

  • Tumor Necrosis Factor Inhibitors

  • Interleukin Inhibitors

  • Vitamin D Analogues

  • Corticosteroids

  • Others

• Treatment Outlook (Revenue, USD Billion, 2021 - 2033)

  • Topicals

  • Systemic

  • Biologics

• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)

  • Oral

  • Parenteral

  • Topical

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Other Pharmacies

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Delivered Customizations

This report has been delivered with the following In-depth customizations